使用促黄体生成素释放激素激动剂进行长期治疗，并将血清睾酮维持在去势浓度。
Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.
作者信息
Labrie F, Dupont A, Belanger A, Lachance R, Giguere M
出版信息
Br Med J (Clin Res Ed). 1985 Aug 10;291(6492):369-70. doi: 10.1136/bmj.291.6492.369.
Abstract
Serum concentrations of luteinising hormone and testosterone were measured by radioimmunoassay one, two, four, seven, and 24 hours after the subcutaneous administration of 500 micrograms of the luteinising hormone releasing hormone agonist [D-Trp6, des-Gly-NH2(10)] LHRH ethylamide or [D-Ser(TBU)6, des-Gly-NH2(10)]LHRH ethylamide in patients who had previously received daily treatment with these peptides for 0, 1, 6, 12, 18, and 24 months. No increase in the serum concentrations of luteinising hormone or testosterone were detected at any time between one and 24 months' treatment. The data show that daily subcutaneous administration of the two luteinising hormone releasing hormone agonists used at the appropriate dose can maintain concentrations of serum androgens equivalent to those after castration during long term treatment.
摘要
在曾接受每日一次这些肽类药物治疗0、1、6、12、18和24个月的患者中，皮下注射500微克促黄体生成素释放激素激动剂[D-色氨酸6，去甘氨酰胺（10）]促黄体生成素释放激素乙酰胺或[D-丝氨酸（叔丁基）6，去甘氨酰胺（10）]促黄体生成素释放激素乙酰胺后1、2、4、7和24小时，通过放射免疫分析法测定血清促黄体生成素和睾酮浓度。在治疗1至24个月期间的任何时间，均未检测到血清促黄体生成素或睾酮浓度升高。数据表明，长期治疗期间，每日皮下注射适当剂量的两种促黄体生成素释放激素激动剂可维持血清雄激素浓度，使其与去势后相当。
相似文献
1
Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.使用促黄体生成素释放激素激动剂进行长期治疗，并将血清睾酮维持在去势浓度。
Br Med J (Clin Res Ed). 1985 Aug 10;291(6492):369-70. doi: 10.1136/bmj.291.6492.369.
2
Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.接受纯抗雄激素治疗的前列腺癌去势患者以及接受促黄体生成素释放激素激动剂和抗雄激素治疗的雌激素预处理患者的血清促黄体生成素（LH）生物活性。
J Clin Endocrinol Metab. 1986 Aug;63(2):297-302. doi: 10.1210/jcem-63-2-297.
3
Loss of luteinizing hormone bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen.用促黄体生成素释放激素（LHRH）激动剂和纯抗雄激素治疗的前列腺癌患者中促黄体生成素生物活性的丧失。
Clin Endocrinol (Oxf). 1986 Jan;24(1):21-30. doi: 10.1111/j.1365-2265.1986.tb03250.x.
4
Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.氟他胺可消除接受促黄体激素释放激素激动剂治疗的前列腺癌患者疾病复发的风险。
J Urol. 1987 Oct;138(4):804-6. doi: 10.1016/s0022-5347(17)43380-5.
5
Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.联合治疗在既往未接受治疗及已接受治疗的晚期前列腺癌患者中的优势。
J Steroid Biochem. 1986 Nov;25(5B):877-83. doi: 10.1016/0022-4731(86)90319-5.
6
Effect of 2-week combination therapy with the luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide and the antiandrogen flutamide on prostate structure and steroid levels in the dog.促黄体生成素释放激素（LHRH）激动剂[D-色氨酸6，去甘氨酰胺（10）]LHRH乙酰胺与抗雄激素氟他胺联合治疗2周对犬前列腺结构和类固醇水平的影响。
Mol Cell Endocrinol. 1989 Dec;67(2-3):131-8. doi: 10.1016/0303-7207(89)90202-5.
7
The rise in testicular androgens during the first days of treatment with an LHRH agonist in the dog can be blocked by aminoglutethimide or ketoconazole.在犬类中，使用促黄体生成素释放激素（LHRH）激动剂治疗的最初几天内，睾丸雄激素的升高可被氨鲁米特或酮康唑阻断。
J Steroid Biochem. 1988 Dec;31(6):963-70. doi: 10.1016/0022-4731(88)90339-1.
8
Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men.成年男性长期经鼻内和皮下给予强效促黄体生成激素释放激素（LH-RH）激动剂对血清雄激素水平的抑制作用。
Fertil Steril. 1982 Mar;37(3):416-24. doi: 10.1016/s0015-0282(16)46107-8.
9
The luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6-Pro9-NEt]LHRH increased rather than lowered LH and alpha-subunit levels in a patient with an LH-secreting pituitary tumor.促黄体生成素释放激素（LHRH）激动剂[D-色氨酸6-脯氨酸9-乙基]LHRH在一名分泌促黄体生成素（LH）的垂体肿瘤患者中升高而非降低了LH和α亚基水平。
J Clin Endocrinol Metab. 1984 Feb;58(2):313-9. doi: 10.1210/jcem-58-2-313.
10
Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.LHRH 激动剂联合氟他胺治疗转移性前列腺癌的内分泌效应
Clin Invest Med. 1988 Oct;11(5):321-6.
引用本文的文献
1
Efficacy of switching therapy of luteinizing hormone-releasing hormone analogue for advanced prostate cancer.促黄体生成素释放激素类似物转换疗法治疗晚期前列腺癌的疗效
Kaohsiung J Med Sci. 2016 Nov;32(11):567-571. doi: 10.1016/j.kjms.2016.09.005. Epub 2016 Nov 4.
2
Changes in Body Image in Patients with Prostate Cancer over 2 Years of Treatment with a Gonadotropin-Releasing Hormone Analogue (Triptorelin): Results from a Belgian Non-Interventional Study.使用促性腺激素释放激素类似物（曲普瑞林）治疗2年的前列腺癌患者身体意象的变化：一项比利时非干预性研究的结果
Drugs Real World Outcomes. 2016 May 13;3(2):183-190. doi: 10.1007/s40801-016-0074-5. eCollection 2016 Jun.
3
Individualized strategy for dosing luteinizing hormone-releasing hormone agonists for androgen-independent prostate cancer: identification of outcomes and costs.黄体生成素释放激素激动剂个体化剂量治疗雄激素非依赖性前列腺癌的策略：结局和成本的确定。
J Oncol Pract. 2006 Mar;2(2):57-66. doi: 10.1200/JOP.2006.2.2.57.
4
Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration.接受抗雄激素氟他胺联合药物（促性腺激素释放激素激动剂）或手术去势的抗激素治疗的前列腺癌患者的性功能变化。
Arch Sex Behav. 1988 Feb;17(1):87-98. doi: 10.1007/BF01542054.
5
Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience.C期和D期前列腺癌的联合治疗：理论依据及五年临床经验
Cancer Metastasis Rev. 1987;6(4):615-36. doi: 10.1007/BF00047470.
6
[Problems and principles of hormone therapy of advanced prostate cancer].[晚期前列腺癌激素治疗的问题与原则]
Klin Wochenschr. 1990 Apr 2;68(7):347-58. doi: 10.1007/BF01650885.
本文引用的文献
1
Endocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases.前列腺癌的内分泌控制；1818例临床与统计调查
J Am Med Assoc. 1950 Aug 12;143(15):1317-20. doi: 10.1001/jama.1950.02910500019005.
2
Cardiovascular complications in the treatment of prostatic carcinoma.
Br J Urol. 1981 Dec;53(6):624-7. doi: 10.1111/j.1464-410x.1981.tb03276.x.
3
Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients.
Scand J Urol Nephrol Suppl. 1980;55:103-5.
4
New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
Clin Invest Med. 1982;5(4):267-75.
5
Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men.成年男性长期经鼻内和皮下给予强效促黄体生成激素释放激素（LH-RH）激动剂对血清雄激素水平的抑制作用。
Fertil Steril. 1982 Mar;37(3):416-24. doi: 10.1016/s0015-0282(16)46107-8.
6
Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer.同时给予纯抗雄激素药物，这是在治疗前列腺癌中使用促黄体生成素释放激素激动剂所必需的组合。
Proc Natl Acad Sci U S A. 1984 Jun;81(12):3861-3. doi: 10.1073/pnas.81.12.3861.
7
New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens.前列腺癌治疗的新方法：完全而非部分去除雄激素。
Prostate. 1983;4(6):579-94. doi: 10.1002/pros.2990040605.
8
Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.促性腺激素释放激素类似物治疗晚期前列腺癌。
Br Med J (Clin Res Ed). 1983 Apr 23;286(6374):1309-12. doi: 10.1136/bmj.286.6374.1309.
9
Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.长期使用促黄体生成素释放激素治疗前列腺癌未能抑制血清促黄体生成素和睾酮。
Br Med J (Clin Res Ed). 1984 Aug 25;289(6443):468-9. doi: 10.1136/bmj.289.6443.468.
10
Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist.晚期前列腺癌：用促性腺激素释放激素激动剂治疗
Br Med J (Clin Res Ed). 1983 May 21;286(6378):1607-9. doi: 10.1136/bmj.286.6378.1607.
Zotero 插件